Penn spinout Peroxitech raises $25M to advance novel drug to treat acute lung injury
Penn spinout Peroxitech raised $25M to further develop its novel drug candidate, PIP-2.
Penn Spinout Verismo Therapeutics Creates New R&D Facility in CIC on Market St
Verismo plans to use this space for its in-house translational research.
Penn Spinout Avisi Technologies Raises $4.06 Million in Seed Round To Be Used to Develop Glaucoma Treatment Device
Avisi was founded in 2017 by Penn students Rui Jing J., the company's CEO, and Brandon Kao and Adarsh Battu, who were studying business and engineering.
Avisi Technologies Closes $4 Million Seed Round to Further Develop Glaucoma Treatment Device
Penn spinout Avisi Technologies raised $4.06 million in a seed round led by Accanto Partners.
Neuralert Technologies included in TIME’s List of the Best Inventions
The lightweight, non-invasive wristband device can detect the stroke symptoms in as little as 15 minutes.
PCI Ventures Presents at Pennovation Works Showcase
The PCI Ventures at Pennovation Works Showcase took place in October 2022, in celebration of Pennovation Works' 6th Anniversary and PCI Ventures' 12 years of service to the Penn community.
Penn spinout and I-Corps participant NeuroFlow raises $25 million growth round, doubles headcount and expands into Center City office
The funding will help Neuroflow, a Philadelphia-based mental health startup, make greater investments in research and development, expand its technology platform and increase headcount.
Philadelphia gene therapy company Passage Bio names former Novartis executive as new CEO
Philadelphia gene therapy company Passage Bio appointed Dr. Will Chou, former Novartis executive, as its new CEO.
Penn Spinout and I-Corps Participant Innervace Raises $40 Million for Parkinson’s Disease Research
The funds will allow Innervace to advance their platform and lead asset in Parkinson’s disease, which aims to reconstruct the neuronal circuitry that is lost in Parkinson's patients.
Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
Verismo plans to begin enrolling patients in the first quarter of 2023 at the initial clinical site, the Hospital of the University of Pennsylvania.